Egle Therapeutics Strengthens its Executive Leadership Team With the Appointment of Christophe Quéva, Ph.D., as Chief Executive Officer
Egle Therapeutics, a clinical-stage biotechnology company advancing the next generation of regulatory T cell (Treg)-focused therapies for oncology and autoimmune diseases, today announced the appointment of experienced biotechnology industry executive, Christophe Quéva, Ph.D., as Chief Executive Officer (CEO). With over 20 years of experience in the biotechnology industry, Dr. Quéva brings a wealth of expertise as Egle transitions into the clinic its two lead drug candidates, EGL-001 and EGL-003.
“I am thrilled to join Egle Therapeutics and collaborate with a team renowned for its deep scientific expertise in regulatory T cells and its strong track record in developing innovative drug candidates for immunology and oncology,” said Christophe Quéva, Ph.D. “Egle is uniquely positioned to demonstrate the therapeutic potential of harnessing regulatory T cells for treating both cancer and autoimmune diseases.”
“As we transition from a company with preclinical assets to a fully-fledged clinical-stage biotech, we will benefit greatly from Christophe's deep operational and strategic expertise. We are delighted to welcome Christophe to the Egle team and look forward to the successes he will drive,” said Vincent Brichard, M.D., Egle’s Interim CEO and Board member.
“Christophe’s appointment marks a pivotal moment for Egle, as we focus on clinical development and advancing our technology platform, his experience, knowledge and networks of the sector will ensure Egle continues to shape its future," said Michel Detheux, Chairman of the board.
Christophe Quéva, Ph.D.
Dr. Christophe Quéva brings over two decades of experience in immuno-oncology, spanning portfolio development from target identification to clinical trials and regulatory approvals. Before joining Egle, he founded and led Ovie Therapeutics, a company focused on an innovative treatment for brain cancer. Since 2022, he has also served as Chief Scientific Officer at DEM BioPharma, driving the development of cancer macrophage-targeting therapies. Prior to this, Dr. Quéva was Chief Scientific Officer at Oncorus, where he advanced next-generation immunotherapies using oncolytic viruses and RNA therapeutics. He also held the same role at iTeos Therapeutics, overseeing the development of a groundbreaking immuno-oncology portfolio.
Earlier in his career, Dr. Quéva held leadership roles at Gilead Sciences, Amgen, and AstraZeneca, contributing to oncology and inflammation drug discovery. He holds a Ph.D. in Life and Health Sciences from the University of Lille in France and completed postdoctoral research in cancer biology at the Fred Hutchinson Cancer Research Center. Dr. Quéva’s extensive career includes numerous patents and publications in the oncology field, reflecting his commitment to advancing patient care through innovative science and leadership.
About Egle Therapeutics SAS (Egle)
Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle is evaluating its most advanced drug candidate in oncology, EGL-001 (a Treg-selective anti-CTLA4-IL-2m), in a Phase I/II clinical trial. In autoimmunity, Egle has completed IND-enabling studies for, EGL-003 (an IL-2 Treg engager), and is poised to commence a clinical trial in 2025.
Find out more at www.egle-tx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113580621/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AEM Launches WMO-Compliant Automated Weather Station to Elevate Global Weather Monitoring13.1.2025 16:00:00 CET | Press release
AEM, the essential source for environmental insights, today announced its WMO-compliant AEM Apex Automated Weather Station (AWS). This state-of-the-art solution sets a new benchmark for precision, reliability, and durability, meeting the strict standards of the World Meteorological Organization (WMO). Designed to address the toughest challenges in weather monitoring, the WMO-compliant AWS offers unparalleled accuracy and performance for a variety of critical applications, from localized climate research to large-scale weather networks. Key Benefits of the WMO-Compliant AWSPrecision Data for Better Decisions: Provides WMO-compliant measurements with strict tolerances to support critical applications. Seamless Global Collaboration: Enables efficient data sharing with regional and global partners, fostering enhanced coordination for monitoring and forecasting. Reliability in Extreme Conditions: Built to deliver continuous, accurate data with minimal maintenance, even in the most demanding
Greenland Resources Signs Advisory Agreement With Rasmussen Global on Defense13.1.2025 15:30:00 CET | Press release
Greenland Resources Inc. (Cboe CA: MOLY | FSE: M0LY) “Greenland Resources” or the “Company”) is pleased to announce that it has signed an advisory agreement with Rasmussen Global to complement the Malmbjerg Project existing funding strategy through potential strategic supranational partners, including the North Atlantic Treaty Organization (NATO) Innovation Fund and the European Defense Fund. Rasmussen Global was founded and is chaired by Anders Fogh Rasmussen, the former Prime Minister of Denmark and former Secretary General of NATO. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113410398/en/ The Project is strategically located in east central Greenland and based on its current NI 43-101 Feasibility Study, can supply some 25% of the European Union (EU) total molybdenum consumption for decades to come including nearly all the EU defense needs. Currently, the EU is the 2nd largest molybdenum user in the world and has no
Starr Names Peter Hirs to Succeed Howard Smith as CFO13.1.2025 15:30:00 CET | Press release
Starr announced that Peter Hirs has been named the company’s chief financial officer, effective January 13, succeeding Howard I. Smith, who is retiring after more than 40 years at Starr and related entities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113071409/en/ Peter Hirs, chief financial officer, Starr (Photo: Business Wire) Hirs brings significant finance and insurance experience to Starr, having spent the past 20 years at a global insurance carrier, where he managed regional finance teams across the world and led mergers and acquisitions activities. In his new role, Hirs will oversee the organization’s global finance operations. He is based at Starr’s head office in New York. Smith had led Starr’s financial operations since 2005, when Maurice R. “Hank” Greenberg, Starr’s chairman emeritus, re-established Starr as a free-standing investment and insurance organization, and he worked closely with Hank prior to that
Moody’s to Acquire CAPE Analytics, Adding AI-Powered Geospatial Property Risk Intelligence to Its Industry-Leading Insurance Risk Models13.1.2025 14:00:00 CET | Press release
Moody’s Corporation (NYSE:MCO) announced today that it has entered into an agreement to acquire CAPE Analytics, a leading provider of geospatial AI intelligence for residential and commercial properties. The acquisition will bring together Moody’s industry-leading Intelligent Risk Platform and catastrophe risk modeling for the insurance sector with CAPE's cutting-edge geospatial AI analytics, creating a sophisticated property database capable of delivering instant, address-specific risk insights. “I continually hear from our customers that they are seeking more precise and actionable information as they evaluate an evolving set of risks,” said Rob Fauber, President and Chief Executive Officer of Moody’s. “By combining our CAT risk models with CAPE’s AI-powered property risk intelligence, we will provide our customers with the most advanced property risk analytics available in the industry, enhancing insights and decision-making across the insurance lifecycle.” With the acquisition of C
Landmark Clinical Study Validates Patch-Based Onera Home-Polysomnography System in One of the Largest Sleep Diagnostic Trials of the Decade13.1.2025 14:00:00 CET | Press release
Study demonstrates comparable performance between wireless, patch-based Onera Sleep Test System and in-lab polysomnography for sleep staging and respiratory event detection. Onera Health, a leader in transforming sleep medicine and remote monitoring, today announced the publication of a multicenter validation study of its Onera Sleep Test System (STS) in the Journal of Clinical Sleep Medicine, the official journal of the American Academy of Sleep Medicine. The study demonstrated that the patch-based Onera STS home-polysomnography (hPSG) performs comparably to gold-standard in-lab polysomnography (PSG) for both sleep staging and respiratory event detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113111691/en/ A woman is conducting a sleep test (polysomnography) using the patch-based Onera STS hPSG system. (Photo: Business Wire) The international multicenter study was managed by an independent Clinical Research Orga
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom